JPWO2020006449A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006449A5 JPWO2020006449A5 JP2020573044A JP2020573044A JPWO2020006449A5 JP WO2020006449 A5 JPWO2020006449 A5 JP WO2020006449A5 JP 2020573044 A JP2020573044 A JP 2020573044A JP 2020573044 A JP2020573044 A JP 2020573044A JP WO2020006449 A5 JPWO2020006449 A5 JP WO2020006449A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding fragment
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 126
- 239000000427 antigen Substances 0.000 claims description 123
- 102000036639 antigens Human genes 0.000 claims description 123
- 108091007433 antigens Proteins 0.000 claims description 123
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 99
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 86
- 102100034256 Mucin-1 Human genes 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 28
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 26
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 26
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 26
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 24
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 22
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 22
- 238000002965 ELISA Methods 0.000 claims description 20
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 18
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 18
- 201000010881 cervical cancer Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 9
- 239000000611 antibody drug conjugate Substances 0.000 claims description 9
- 210000000013 bile duct Anatomy 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000010982 kidney cancer Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 201000002510 thyroid cancer Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 206010046766 uterine cancer Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691887P | 2018-06-29 | 2018-06-29 | |
| US62/691,887 | 2018-06-29 | ||
| US201962802865P | 2019-02-08 | 2019-02-08 | |
| US62/802,865 | 2019-02-08 | ||
| PCT/US2019/039883 WO2020006449A1 (en) | 2018-06-29 | 2019-06-28 | Anti-glyc0-muc1 antibodies and their uses |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529524A JP2021529524A (ja) | 2021-11-04 |
| JPWO2020006449A5 true JPWO2020006449A5 (https=) | 2022-07-06 |
| JP2021529524A5 JP2021529524A5 (https=) | 2022-07-06 |
| JP7541930B2 JP7541930B2 (ja) | 2024-08-29 |
Family
ID=68987626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573044A Active JP7541930B2 (ja) | 2018-06-29 | 2019-06-28 | 抗グリコｍｕｃ１抗体およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12269892B2 (https=) |
| EP (1) | EP3814384A4 (https=) |
| JP (1) | JP7541930B2 (https=) |
| CN (1) | CN112996816B (https=) |
| WO (1) | WO2020006449A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4114860A1 (en) * | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| BR112023001739A2 (pt) * | 2020-07-31 | 2023-02-28 | Scherer Technologies Llc R P | Anticorpo específico para mucina-1 e métodos de uso do mesmo |
| AU2022420709A1 (en) * | 2021-12-21 | 2024-08-01 | Merus B.V. | Binding domains against cancer-associated muc1 |
| WO2025114381A1 (en) * | 2023-11-27 | 2025-06-05 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Muc1 antibodies and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE123066T1 (de) | 1988-03-11 | 1995-06-15 | Biomembrane Inst | Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden- trägerkonjugaten. |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| WO2001075110A2 (en) | 2000-03-30 | 2001-10-11 | Dyax Corp. | Mucin-1 specific binding members and methods of use thereof |
| US7338932B2 (en) | 2000-05-11 | 2008-03-04 | Glycozym Aps | Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| CN1141142C (zh) * | 2001-02-08 | 2004-03-10 | 北京迪威华宇生物技术有限公司 | 人乳腺癌muc-1抗原基因工程疫苗 |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| EP2083868A2 (en) | 2006-10-04 | 2009-08-05 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2014302A1 (en) | 2007-07-12 | 2009-01-14 | Institut Curie | An antibody specific for the Tn antigen for the treatment of cancer |
| TWI405770B (zh) * | 2007-07-31 | 2013-08-21 | Glytech Inc | Production of peptides |
| JP5532401B2 (ja) | 2007-12-05 | 2014-06-25 | 協和発酵キリン株式会社 | ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP5773352B2 (ja) | 2008-10-28 | 2015-09-02 | 塩野義製薬株式会社 | 抗ｍｕｃ１抗体 |
| TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| WO2011054359A2 (en) * | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
| JP5660486B2 (ja) | 2010-02-12 | 2015-01-28 | 国立大学法人 鹿児島大学 | ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途 |
| EP2565268A4 (en) | 2010-04-28 | 2013-10-09 | Shionogi & Co | NEW MUC1 ANTIBODY |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| EP2855531A1 (en) | 2012-05-24 | 2015-04-08 | F. Hoffmann-La Roche AG | Multispecific antibodies |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| EP2981281B1 (en) * | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| US20170145108A1 (en) | 2014-02-05 | 2017-05-25 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| AU2015254257B2 (en) | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| US20170129962A1 (en) | 2015-10-02 | 2017-05-11 | Hoffmann-La Roche Inc. | Multispecific antibodies |
| EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| AU2018241781A1 (en) | 2017-03-29 | 2019-07-18 | Glycotope Gmbh | Multispecific antibody constructs binding to MUC1 and CD3 |
-
2019
- 2019-06-28 JP JP2020573044A patent/JP7541930B2/ja active Active
- 2019-06-28 WO PCT/US2019/039883 patent/WO2020006449A1/en not_active Ceased
- 2019-06-28 EP EP19826976.3A patent/EP3814384A4/en active Pending
- 2019-06-28 US US17/256,326 patent/US12269892B2/en active Active
- 2019-06-28 CN CN201980056864.6A patent/CN112996816B/zh active Active
-
2025
- 2025-03-03 US US19/068,368 patent/US20250304716A1/en active Pending